ERBB2 and breast cancer: EMILIA, a phase III trial, compared the efficacy of T-DM1 alone vs. lapatinib + capecitabine in HER2-positive advanced BC previously treated with trastuzumab and a taxane, and it showed that the T-DM1 group had improvements in PFS and OS (p < 0.001).